Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: Dihydro-7-hydroxymitragynine, Dihydro-7-hydroxy mitragynine, DH-7OH-MIT, DHM, 1,2-Dihydro-7-hydroxymitragynine
MGM-15, chemically identified as methyl (E)-2-((2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-1,2,3,4,6,7,7a,12,12a,12b-decahydroindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate, is a semi-synthetic derivative of 7-hydroxymitragynine. It was described in preclinical medicinal-chemistry research as a dual μ-opioid-receptor and δ-opioid-receptor agonist. Human clinical studies, established therapeutic use, and FDA approval were not identified in the authoritative sources reviewed.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
The foundational research evaluated MGM-15 in nonhuman preclinical systems, including receptor-binding or functional assays and animal studies. No reliable human pharmacokinetic half-life, clinical onset, validated therapeutic regimen, standardized catalog presentation, or authoritative storage specification was identified. The 2025 study found an average of 10.9 ± 0.2 mg MGM-15 in analyzed commercially available tablets, but this is an analytical observation about tested products rather than an established reference size and is not used as a common size here.
Supplementary research context only. Not medical advice or a treatment recommendation.
CAS RN: 1158901-38-2; PubChem CID: 42629165; molecular formula: C23H32N2O5; molecular weight: 416.518 g/mol; InChIKey: QXFXDJATKPXTFF-LIMHOZKTSA-N; SMILES: CC[C@@H]1CN2CC[C@]3([C@@H]([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC)O; IUPAC name: methyl (E)-2-[(2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12,12a,12b-octahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate.
MGM-15 is not reported as a naturally occurring primary kratom alkaloid; it is produced by chemical modification of mitragynine-related starting materials. Preclinical studies characterize it as an opioid-receptor-active compound. In the United States, the DEA temporarily placed MGM-15 and specified related forms in Schedule I effective August 26, 2026, through August 26, 2028, unless extended or made permanent.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention MGM-15 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.